Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lilly to develop Xencor proteins
Xencor used its proprietary protein design automation (PDA) technology to optimize the physical and biochemical properties of an undisclosed therapeutic protein. In less than 12 months, Xencor created
Xencor used its proprietary protein design automation (PDA) technology to optimize the physical and biochemical properties of an undisclosed therapeutic protein. In less than 12 months, Xencor created
The CD33 antigen is expressed on a number of hematologic malignancies, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome and several myeloproliferative disorders. Due to
This development in the collaboration, which was contingent on Pharmacopeia meeting all pre-determined drug candidate criteria, has triggered an undisclosed cash milestone payment to Pharmacopeia. Pharmacopeia will receive
As part of its new strategic direction, Questcor will initially focus its sales and marketing resources on promoting its multiple sclerosis treatment HP Acthar Gel (repository corticotropin injection)
The trial will evaluate the maximum tolerated dose (MTD) and dose-limiting toxicities of Cloretazine (VNP40101M) administered daily for five consecutive days every six weeks in children with recurrent,
In the study, Lamictal (lamotrigine) was given to patients inadequately controlled with one or two concurrent antiepileptic drugs (AEDs). Study results show Lamictal significantly reduced primary generalized tonic-clonic
The new drug, AD 237, targets chronic obstructive pulmonary disease (COPD), a respiratory disease primarily caused by smoking. While Arakis has been developing AD 237, Vectura owns the
The co-promotion agreement provides that Kos and Duramed Pharmaceuticals, a subsidiary of Barr, will co-promote the current Niaspan and Advicor products, as well as future dosage formulations, strengths
Under the terms of the deal, KineMed will screen numerous molecules provided by the library of Sosei’s drug reprofiling platform (DRP) using its proprietary in vivo KineMarker assays.
Celadrin, developed by Imagenetix, is a proprietary fatty acid complex useful in promoting joint health. It has been approved for use as a pharmaceutical product in India to